Cautious. GSK trades as a mature Value Compounder (65/100) with stable dividend appeal, but modest Growth Compounder signals (52.5) reflect slowing pharma pipelines and patent cliff headwinds. Leadership alignment is adequate (60.3), though no founder-CEO alignment amplifies reliance on execution. Financial vulnerability is manageable, but thin operational moat in commoditized generics and late-stage pipeline visibility remain structural concerns. Suitable for income, not growth.
Every stock is scored across six proprietary dimensions built for retail investors who want Buffett-quality analysis without a Bloomberg subscription. Here's the actual snapshot for GSK PLC ORD 31 1/4P:
Quality + moat + leadership + valuation + sentiment fused into a single 0–100 number. When you see 59/100, you know instantly whether to dig deeper or skip.
Pricing power, switching costs, network effects, and 10-year ROIC data. Same framework Morningstar charges for — free inside Stocky.
Founder tenure, insider ownership, CEO pay reasonableness, long-term value creation. Six factors, one score — turns "trust the CEO" into evidence.
Customer concentration, supply chain, refinancing walls, regulatory exposure. Stocky maps knowable fragilities so you're never blindsided.
Every score backtested against real S&P 500 returns. See how "Elite" (90+ Verdict) picks have performed vs the index — no black boxes.
Analyst target shifts, insider buys, big moves — plus a monthly Portfolio Health Report telling you what's actually driving your returns.
Stocky rates GSK PLC ORD 31 1/4P (GSK.L) at 59/100 — below the bar Stocky looks for. The score fuses business quality, moat width, leadership alignment, valuation and analyst signal into a single number. Cautious. GSK trades as a mature Value Compounder (65/100) with stable dividend appeal, but modest Growth Compounder signals (52.5) reflect slowing pharma pipelines and patent cliff headwinds. Leadership alignment is adequate (60.3), though
GSK.L's current Stocky Verdict is 59/100, placing it in the "Cautious" band. This composite combines a 65/100 Compounder score, 60/100 Leadership, Moat rating, and analyst signal.
Stocky hasn't finalised a Moat Score for GSK PLC ORD 31 1/4P yet — the analysis draws from ROIC trends, pricing power evidence, and competitive-position filings.
GSK PLC ORD 31 1/4P scores 60/100 on Leadership Alignment. Higher = more founder involvement, higher insider ownership, sensible pay, and evidence of long-term capital allocation discipline.
GSK PLC ORD 31 1/4P's Vulnerability Profile scores 50/100 (higher = more resilient). The profile flags customer concentration, supply chain, refinancing walls and regulatory risks specific to GSK PLC ORD 31 1/4P.
Sign up free and unlock the full analysis on GSK.L — the same tools professional analysts use, personalised to your portfolio:
Free forever tier includes 5 Verdict lookups a day. Plus €19/mo unlocks everything above. Cancel any time.
Or jump straight to the interactive dashboard for GSK.L in the app.
